It is projected that the HIV/HBV/HCV test kits market size will be valued US$ 6,568.3 million in 2023 and US$ 11,573,9 million in 2033. It is projected that sales of test kits for HIV/HBV/HCV would rise at a noteworthy compound annual growth rate (CAGR) of 5.8% during the forecast period.
The global incidence of HIV and hepatitis has increased significantly, and this is expected to drive HIV/HBV/HCV test kit consumption. With HIV and hepatitis infections being major public health issues around the world, there is a high demand for effective diagnostic services for these diseases.
- According to the WHO’s June 2022 report, an estimated 58 million people worldwide have chronic hepatitis C virus infection, with approximately 1.5 million new cases occurring each year. An estimated 3.2 million adolescents and children are infected with chronic hepatitis C. The disease’s high prevalence is expected to drive market growth.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-9814
Governments and non-governmental organizations (NGOs) all over the world are taking steps to raise awareness about STD testing and its significance in the fight against HIV and hepatitis.
- This has resulted in a significant increase in global awareness, with initiatives such as ‘Start Talking. Stop HIV/AIDS’ and “World Hepatitis Day” every year to increase awareness and understanding of these chronic diseases.
Since early diagnosis improves disease treatment, these awareness campaigns are expected to increase demand for HIV/HBV/HCV test kits globally and accelerate market growth.
Rising medical diagnostics research and development, rising HIV and hepatitis incidence, increased awareness among the general population, increasing medical expenditure, technological developments in diagnostics, and other major factors are expected to drive consumption of HIV/HBV/HCV test kits.
Key Takeaways from the HIV/HBV/HCV Test Kits Market
- The North America HIV/HBV/HCV test kits market accounts for a dominant market position in the global marketplace, with a share of 33.4% in 2022, and is expected to maintain this position throughout the forecast period. Rising cases of sexually transmitted infections (STIs) and sexually transmitted diseases (STDs) in the region are responsible for HIV/HBV/HCV test kit sales significantly.
- The blood sample segment is anticipated to witness a strong growth of 6.1% during the 2023-2033 period. The primary reason for the expansion of this segment is the increased number of tests required prior to blood or blood product transfusion. The increasing use of serological tests for blood group typing, as well as mandatory screening tests for HIV, HCV, HBV, syphilis, and malaria, are driving the segment’s growth.
- East Asian and South Asian markets for HIV/HBV/HCV testing equipment currently account for 21.9% and 6.2% of the global industry, respectively. Sales of HIV/HBV/HCV test kits in these regions are projected to be fueled by densely populated nations such as India and China as their emphasis on healthcare grows.
- The market’s primary part, assay-based test kits, is growing at a 6.4% annual pace. Assay kits are the primary method used for patient testing. Moreover, assay-based testing findings are used by medical professionals and patients in the majority of developing nations.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-9814
Manufacturers are constantly evolving business models
Companies in the HIV/HBV/HCV test kits market are moderately competitive by nature, with several major players present. These players are part of several strategic alliances. The agreement and system automation speed up the manufacturer’s strategy to capitalize on market share and capture a sizable market share.
Latest Developments
- November 2021 – Siemens Healthineers AG and Hemogenomics funded a clinical trial to compare the ADVIA Centaur XP chemiluminescence system for HIV, HCV, and Syphilis screening in blood donors from India.
- NATSpert, an Individual Donor Nucleic Acid Test (ID-NAT) to screen for HIV, HBV, and HCV in donated blood, was launched in April 2019 by Mylab Discovery Solutions.
HIV/HBV/HCV Test Kits Market by Solution
HIV/HBV/HCV Test Kits Market by Test Kit Type:
- Assay-based Test Kits
- Rapid Test Kits
HIV/HBV/HCV Test Kits Market by Sample:
- Blood
- Urine
- Saliva
HIV/HBV/HCV Test Kits Market by End User:
- HIV/HBV/HCV Test Kits for Hospitals
- HIV/HBV/HCV Test Kits for Clinics
- HIV/HBV/HCV Test Kits for Diagnostic Laboratories
- HIV/HBV/HCV Test Kits for Government Organizations and NGOs
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube